{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:16:28Z","timestamp":1787318188073,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU15\/03434"],"award-info":[{"award-number":["FPU15\/03434"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0012\/0012"],"award-info":[{"award-number":["RD16\/0012\/0012"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/00442"],"award-info":[{"award-number":["PI14\/00442"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0012\/0014"],"award-info":[{"award-number":["RD16\/0012\/0014"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The presence of rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) autoantibodies contributes to the current rheumatoid arthritis (RA) classification criteria. These criteria involve stratification on antibody levels, which limits reproducibility, and underperform in the RA patients without RF and anti-CCP. Here, we have explored if two anti-acetylated peptide antibodies (AAPA), anti-acetylated lysine (AcLys) and anti-acetylated ornithine (AcOrn), could improve the performance of the current criteria. The analysis was done in 1062 prospectively-followed early arthritis (EA) patients. The anti-AcOrn were more informative than the anti-AcLys, the conventional RA antibodies and the anti-carbamylated protein antibodies. The anti-AcOrn produced a classification that did not require antibody levels and showed improved specificity (77.6%\n                    <jats:italic>vs.<\/jats:italic>\n                    72.6%, p\u2009=\u20090.003) and accuracy (79.0%\n                    <jats:italic>vs.<\/jats:italic>\n                    75.8%, p\u2009=\u20090.002) over the current criteria. These improvements were obtained with a scoring system that values concordance between anti-AcOrn, RF and anti-CCP. No significant gain was obtained in sensitivity (80.2%\n                    <jats:italic>vs.<\/jats:italic>\n                    78.8%, p\u2009=\u20090.25) or in improving the classification of the RA patients lacking RF and anti-CCP, although the anti-AcOrn ranked first among the analysed new antibodies. Therefore, the anti-AcOrn antibodies could contribute to the improvement of RA classification criteria by exploiting antibody concordance.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-73919-y","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T06:02:46Z","timestamp":1604642566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies"],"prefix":"10.1038","volume":"10","author":[{"given":"Lorena","family":"Rodriguez-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Triguero-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Peiteado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Feito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidoro","family":"Gonzalez-Alvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"73919_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"73919_CR2","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheum."},{"key":"73919_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.22583","volume":"67","author":"R Aggarwal","year":"2015","unstructured":"Aggarwal, R. et al. Distinctions between diagnostic and classification criteria?. Arthritis Care Res. (Hoboken) 67, 891\u2013897 (2015).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"73919_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315\u2013324 (1988).","journal-title":"Arthritis Rheum."},{"key":"73919_CR5","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/annrheumdis-2012-201426","volume":"71","author":"AH van der Helm-van Mil","year":"2012","unstructured":"van der Helm-van Mil, A. H. & Huizinga, T. W. The 2010 ACR\/EULAR criteria for rheumatoid arthritis: do they affect the classification or diagnosis of rheumatoid arthritis?. Ann. Rheum. Dis. 71, 1596\u20131598 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/annrheumdis-2013-203284","volume":"73","author":"H Radner","year":"2014","unstructured":"Radner, H., Neogi, T., Smolen, J. S. & Aletaha, D. Performance of the 2010 ACR\/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 73, 114\u2013123 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/annrheumdis-2016-209629","volume":"76","author":"AH van der Helm-van Mil","year":"2017","unstructured":"van der Helm-van Mil, A. H. & Zink, A. What is rheumatoid arthritis? Considering consequences of changed classification criteria. Ann. Rheum. Dis. 76, 315\u2013317 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semarthrit.2017.04.009","volume":"47","author":"DM Boeters","year":"2017","unstructured":"Boeters, D. M., Gaujoux-Viala, C., Constantin, A. & van der Helm-van Mil, A. H. M. The 2010 ACR\/EULAR criteria are not sufficiently accurate in the early identification of autoantibody-negative rheumatoid arthritis: results from the Leiden-EAC and ESPOIR cohorts. Semin. Arthritis Rheum. 47, 170\u2013174 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"73919_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/kev383","volume":"55","author":"M van der Ven","year":"2016","unstructured":"van der Ven, M. et al. Do we need to lower the cut point of the 2010 ACR\/EULAR classification criteria for diagnosing rheumatoid arthritis?. Rheumatology (Oxford) 55, 636\u2013639 (2016).","journal-title":"Rheumatology (Oxford)"},{"key":"73919_CR10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/art.30200","volume":"63","author":"MP van der Linden","year":"2011","unstructured":"van der Linden, M. P. et al. Toward a data-driven evaluation of the 2010 American College of Rheumatology\/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor?. Arthritis Rheum. 63, 1190\u20131199 (2011).","journal-title":"Arthritis Rheum."},{"key":"73919_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/annrheumdis-2015-208873","volume":"76","author":"LB Nordberg","year":"2017","unstructured":"Nordberg, L. B. et al. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-na\u00efve patients classified according to the 2010 ACR\/EULAR criteria. Ann. Rheum. Dis. 76, 341\u2013345 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/rheumatology\/keq442","volume":"50","author":"Y Kaneko","year":"2011","unstructured":"Kaneko, Y., Kuwana, M., Kameda, H. & Takeuchi, T. Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 50, 1268\u20131274 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"73919_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.autrev.2012.05.007","volume":"12","author":"LA Trouw","year":"2012","unstructured":"Trouw, L. A. & Mahler, M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun. Rev. 12, 318\u2013322 (2012).","journal-title":"Autoimmun. Rev."},{"key":"73919_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-019-2079-4","volume":"21","author":"C Regueiro","year":"2019","unstructured":"Regueiro, C. et al. Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: analysis in two early arthritis clinics. Arthritis Res. Ther. 21, 280 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"73919_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-020-02182-3","volume":"22","author":"BT van Dijk","year":"2020","unstructured":"van Dijk, B. T., Trouw, L. A., van der Helm-van Mil, A. H. M. & Huizinga, T. W. J. Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al. Arthritis Res. Ther. 22, 85 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"73919_CR16","doi-asserted-by":"publisher","first-page":"12023","DOI":"10.1038\/s41598-017-09657-5","volume":"7","author":"C Regueiro","year":"2017","unstructured":"Regueiro, C. et al. Value of measuring anti-carbamylated protein antibodies for classification on early arthritis patients. Sci. Rep. 7, 12023 (2017).","journal-title":"Sci. Rep."},{"key":"73919_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13075-018-1591-2","volume":"20","author":"DM Boeters","year":"2018","unstructured":"Boeters, D. M., Trouw, L. A., van der Helm-van Mil, A. H. M. & van Steenbergen, H. W. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example. Arthritis Res. Ther. 20, 94 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"73919_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","volume":"75","author":"M Juarez","year":"2016","unstructured":"Juarez, M. et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann. Rheum. Dis. 75, 1099\u20131107 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2016-209297","volume":"76","author":"CP Figueiredo","year":"2017","unstructured":"Figueiredo, C. P. et al. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann. Rheum. Dis. 76, 399\u2013407 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR20","first-page":"816","volume":"77","author":"P Studenic","year":"2018","unstructured":"Studenic, P. et al. FRI0585 Prevalence of anti-acetylated protein antibodies in inflammatory arthritis, osteoarthritis, connective tissue diseases and its discriminative capacity as diagnostic marker for early rheumatoid arthritis. Ann. Rheum. Dis. 77, 816\u2013817 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR21","first-page":"694","volume":"75","author":"P Studenic","year":"2016","unstructured":"Studenic, P. et al. SAT0081 The diagnostic and predictive value of anti-acetylated peptide antibodies (AAPA) in rheumatoid arthritis patients starting their first DMARD treatment on methotrexate. Ann. Rheum. Dis. 75, 694 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-018-1520-4","volume":"20","author":"EC de Moel","year":"2018","unstructured":"de Moel, E. C. et al. Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. Arthritis Res. Ther. 20, 33 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"73919_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-019-1815-0","volume":"21","author":"EC de Moel","year":"2019","unstructured":"de Moel, E. C. et al. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res. Ther. 21, 28 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"73919_CR24","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/art.40562","volume":"70","author":"MK Verheul","year":"2018","unstructured":"Verheul, M. K. et al. Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals. Arthritis Rheumatol. 70, 1721\u20131731 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"73919_CR25","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi, J. et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl. Acad. Sci. USA 108, 17372\u201317377 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73919_CR26","doi-asserted-by":"publisher","first-page":"e0161141","DOI":"10.1371\/journal.pone.0161141","volume":"11","author":"A Montes","year":"2016","unstructured":"Montes, A. et al. Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies. PLoS ONE 11, e0161141 (2016).","journal-title":"PLoS ONE"},{"key":"73919_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/ard.2006.051391","volume":"65","author":"J Avouac","year":"2006","unstructured":"Avouac, J., Gossec, L. & Dougados, M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 65, 845\u2013851 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR28","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1002\/art.23763","volume":"58","author":"A Ioan-Facsinay","year":"2008","unstructured":"Ioan-Facsinay, A. et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 58, 3000\u20133008 (2008).","journal-title":"Arthritis Rheum."},{"key":"73919_CR29","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/acr.22385","volume":"66","author":"C Terao","year":"2014","unstructured":"Terao, C. et al. Effects of smoking and shared epitope on the production of anti-citrullinated peptide antibody in a Japanese adult population. Arthritis Care Res. (Hoboken) 66, 1818\u20131827 (2014).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"73919_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/annrheumdis-2011-200668","volume":"71","author":"L \u00c4rlestig","year":"2012","unstructured":"\u00c4rlestig, L. et al. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann. Rheum. Dis. 71, 825\u2013829 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR31","doi-asserted-by":"publisher","first-page":"e29492","DOI":"10.1371\/journal.pone.0029492","volume":"6","author":"I Gonzalez-Alvaro","year":"2011","unstructured":"Gonzalez-Alvaro, I. et al. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS ONE 6, e29492 (2011).","journal-title":"PLoS ONE"},{"key":"73919_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/rheumatology\/kem343","volume":"47","author":"G Orozco","year":"2008","unstructured":"Orozco, G. et al. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis. Rheumatology (Oxford) 47, 138\u2013141 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"73919_CR33","volume-title":"Model Selection and Multi-model Inference: A Practical Information-Theoretic Approach","author":"DR Anderson","year":"2004","unstructured":"Anderson, D. R. & Burnham, K. Model Selection and Multi-model Inference: A Practical Information-Theoretic Approach (Springer-Verlag, Berlin, 2004)."},{"key":"73919_CR34","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org (2013)."},{"key":"73919_CR35","unstructured":"The jamovi project. jamovi. https:\/\/www.jamovi.org (2019)."},{"key":"73919_CR36","doi-asserted-by":"publisher","first-page":"e101717","DOI":"10.1371\/journal.pone.0101717","volume":"9","author":"L Micallef","year":"2014","unstructured":"Micallef, L. & Rodgers, P. eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses. PLoS ONE 9, e101717 (2014).","journal-title":"PLoS ONE"},{"key":"73919_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-016-1177-9","volume":"18","author":"TJ van Wesemael","year":"2016","unstructured":"van Wesemael, T. J. et al. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Res. Ther. 18, 285 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"73919_CR38","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/art.40852","volume":"71","author":"AK Hedstrom","year":"2019","unstructured":"Hedstrom, A. K., Ronnelid, J., Klareskog, L. & Alfredsson, L. Complex relationships of smoking, HLA-DRB1 genes, and serologic profiles in patients with early rheumatoid arthritis: update from a Swedish population-based case-control study. Arthritis Rheumatol. 71, 1504\u20131511 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"73919_CR39","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41598-020-60305-x","volume":"10","author":"C Regueiro","year":"2020","unstructured":"Regueiro, C. et al. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis. Sci. Rep. 10, 3355 (2020).","journal-title":"Sci. Rep."},{"key":"73919_CR40","doi-asserted-by":"publisher","first-page":"e0180655","DOI":"10.1371\/journal.pone.0180655","volume":"12","author":"D Murphy","year":"2017","unstructured":"Murphy, D., Mattey, D. & Hutchinson, D. Anti-citrullinated protein antibody positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and the shared epitope rather than smoking per se. PLoS ONE 12, e0180655 (2017).","journal-title":"PLoS ONE"},{"key":"73919_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cccn.2004.07.016","volume":"350","author":"S Nijenhuis","year":"2004","unstructured":"Nijenhuis, S., Zendman, A. J. W., Vossenaar, E. R., Pruijn, G. J. M. & vanVenrooij, W. J. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin. Chim. Acta 350, 17\u201334 (2004).","journal-title":"Clin. Chim. Acta"},{"key":"73919_CR42","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar1149","volume":"6","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar, E. R. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 6, R142\u2013R150 (2004).","journal-title":"Arthritis Res. Ther."},{"key":"73919_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/bmj.2.6182.97","volume":"2","author":"BJ Young","year":"1979","unstructured":"Young, B. J., Mallya, R. K., Leslie, R. D., Clark, C. J. & Hamblin, T. J. Anti-keratin antibodies in rheumatoid arthritis. BMJ 2, 97\u201399 (1979).","journal-title":"BMJ"},{"key":"73919_CR44","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI117969","volume":"95","author":"M Sebbag","year":"1995","unstructured":"Sebbag, M. et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Investig. 95, 2672\u20132679 (1995).","journal-title":"J. Clin. Investig."},{"key":"73919_CR45","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3389\/fimmu.2018.03033","volume":"9","author":"KA Lloyd","year":"2018","unstructured":"Lloyd, K. A. et al. Differential ACPA binding to nuclear antigens reveals a PAD-independent pathway and a distinct subset of acetylation cross-reactive autoantibodies in rheumatoid arthritis. Front. Immunol. 9, 3033 (2018).","journal-title":"Front. Immunol."},{"key":"73919_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216499","author":"T Kissel","year":"2020","unstructured":"Kissel, T. et al. Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216499 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"73919_CR47","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/art.40699","volume":"71","author":"J Steen","year":"2019","unstructured":"Steen, J. et al. Recognition of amino acid motifs, rather than specific proteins, by human plasma cell-derived monoclonal antibodies to posttranslationally modified proteins in rheumatoid arthritis. Arthritis Rheumatol. 71, 196\u2013209 (2019).","journal-title":"Arthritis Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73919-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73919-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73919-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:33:46Z","timestamp":1670348026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73919-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73919"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73919-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Holger Bang is employee of the diagnostic company Orgentec Diagnostika. Alejandro Balsa has received grant\/research support from: Abbvie, Pfizer, Novartis, BMS, Nordic, Sanofi; Consultant for: Abbvie, Pfizer, Novartis, BMS, Nordic, Sanofi, Sandoz, Lilly; Paid instructor for: Pfizer; Speakers bureau: Pfizer, Novartis, UCB, Nordic, Sanofi, Sandoz, Lilly. Isidoro Gonzalez-Alvaro has received personal fees from Lilly and Sanofi; personal fees and non-financial support from BMS, Abbvie, and Roche Laboratories; non-financial support from MSD, Pfizer and Novartis. Antonio Gonzalez has received research support and speaker fees from BMS. The other authors declare no financial interests that could create a potential conflict of interest or the appearance of a conflict of interest regarding this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19263"}}